Stories
Pharma Body Seeks Holistic Healthcare Pricing Review After Cancer Drug Price Caps
C
CNBC TV18•19-10-2026, 17:23
Pharma Body Seeks Holistic Healthcare Pricing Review After Cancer Drug Price Caps
- •The Indian Pharmaceutical Alliance has called for a comprehensive review of healthcare pricing following the NPPA's decision to cap trade margins at 30 percent for 137 cancer drugs.
- •The revised maximum retail prices take effect on November 9, aiming to make cancer treatments significantly more affordable and save patients approximately 2500 crore rupees.
- •Sudarshan Jain noted that healthcare pricing involves complex factors including medicine prices, distribution costs, and hospital expenses, which must be evaluated together.
- •While manufacturers may not face direct impacts as they supply at stockist prices, hospitals could experience shifts in business models where medicine and diagnostic revenues cover other costs.
- •Jain cautioned that future price reductions must be carefully assessed to protect affordability while maintaining the industry's economic viability and global competitiveness.
Key Questions Answered
The National Pharmaceutical Pricing Authority (NPPA) has capped trade margins at 30% for 137 non-scheduled cancer drugs. This regulatory action is expected to reduce maximum retail prices by up to 70% and generate approximately ₹2,500 crore in annual savings for patients.
The revised maximum retail prices (MRPs) resulting from the trade margin rationalization are scheduled to take effect from November 9.
The Indian Pharmaceutical Alliance (IPA) requested a holistic review to assess healthcare pricing comprehensively by factoring in medicine prices, distribution costs, and hospital expenses together. They cautioned that future price reductions must be carefully evaluated to protect the industry's economic viability and global competitiveness.
